Receptor paralyzing agents applied in the treatment of glaucoma simplex.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001369:Axons / Q000166:cytology; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004837:Epinephrine / Q000627:therapeutic use*; D005123:Eye / Q000294:innervation; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008854:Microscopy, Electron; D010862:Pilocarpine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use*; D011955:Receptors, Drug; D013564:Sympathetic Nervous System / Q000473:pathology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D011955:Receptors, Drug; D010862:Pilocarpine; D011433:Propranolol; D004837:Epinephrine